NCT07024173View on ClinicalTrials.gov

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 23, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Locally Advanced Breast CancerMetastatic Breast Cancer
Interventions
DRUG

HRS-8080 Tablet

HRS-8080 tablet orally administered.

DRUG

Fulvestrant injection

Fulvestrant injection.

DRUG

Exemestane tablets

Exemestane tablets orally administered.

DRUG

Everolimus Tablets

Everolimus tablets orally administered.

Trial Locations (2)

410000

RECRUITING

Hunan Cancer Hospital, Changsha

510000

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY